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COMMENTARY
The need for a network to establish 
and validate predictive biomarkers in cancer 
immunotherapy
Giuseppe V. Masucci1* , Alessandra Cesano2, Alexander Eggermont3, Bernard A. Fox4, Ena Wang5, 
Francesco M. Marincola6, Gennaro Ciliberto7, Kevin Dobbin8, Igor Puzanov9, Janis Taube10, Jennifer Wargo11, 
Lisa H. Butterfield12, Lisa Villabona1, Magdalena Thurin13, Michael A. Postow14,15,16, Paul M. Sondel17, 
Sandra Demaria18, Sanjiv Agarwala19 and Paolo A. Ascierto20*
Abstract 
Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, the 
entire medical oncology field has been revolutionized by the introduction of immune checkpoints inhibitors. Despite 
success in a variety of malignancies, responses typically only occur in a small percentage of patients for any given 
histology or treatment regimen. There are also concerns that immunotherapies are associated with immune-related 
toxicity as well as high costs. As such, identifying biomarkers to determine which patients are likely to derive clinical 
benefit from which immunotherapy and/or be susceptible to adverse side effects is a compelling clinical and social 
need. In addition, with several new immunotherapy agents in different phases of development, and approved thera-
peutics being tested in combination with a variety of different standard of care treatments, there is a requirement to 
stratify patients and select the most appropriate population in which to assess clinical efficacy. The opportunity to 
design parallel biomarkers studies that are integrated within key randomized clinical trials could be the ideal solu-
tion. Sample collection (fresh and/or archival tissue, PBMC, serum, plasma, stool, etc.) at specific points of treatment 
is important for evaluating possible biomarkers and studying the mechanisms of responsiveness, resistance, toxicity 
and relapse. This white paper proposes the creation of a network to facilitate the sharing and coordinating of samples 
from clinical trials to enable more in-depth analyses of correlative biomarkers than is currently possible and to assess 
the feasibilities, logistics, and collated interests. We propose a high standard of sample collection and storage as well 
as exchange of samples and knowledge through collaboration, and envisage how this could move forward using 
banked samples from completed studies together with prospective planning for ongoing and future clinical trials.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Concept 1. The need for biomarker discovery 
and validation in cancer immunotherapy
Immunotherapies have emerged as one of the most 
promising approaches to treat patients with cancer. 
Recently, the entire medical oncology field has been revo-
lutionized by the introduction of immune checkpoint 
inhibitors, including T cell inhibitory receptors such as 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) 
and programmed cell death-1 (PD-1) or its ligand (PDL-
1). However, despite well documented success in a vari-
ety of malignancies, responses typically only occur in a 
small percentage of patients for any given histology or 
treatment regimen. There are also concerns associated 
with immune-related toxicity and the high cost of immu-
notherapies. Because of this, identifying biomarkers to 
determine those patients that are most likely to derive 
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those who are more prone to develop adverse side effects 
is a compelling clinical and social need. Moreover, with 
several new immunotherapy agents in different phases 
of development, and approved therapies being evaluated 
in various combinations with different standard of care 
treatments, there is an urgent requirement to stratify 
patients and select the most appropriate populations in 
which to assess clinical efficacy.
Because of the complexity of the immune response, 
tumor heterogeneity and patient diversity, it is unlikely 
that a single biomarker will be sufficient to predict clini-
cal outcomes in response to the spectrum of immune-
targeted therapies. Biomarkers which are correlated with 
clinical outcome can be identified at molecular (genetics, 
epigenetics, metagenomics, proteomic, metabolomics, 
etc.), cellular and tissue levels. Before a candidate bio-
marker and/or new technology can be used for treatment 
decisions in a clinical setting, several steps are necessary 
to demonstrate its clinical validity. The discovery and 
assessment of biomarkers using cutting edge technolo-
gies across different clinical studies is a fundamental step 
in maximizing data generation. Collaborative efforts to 
combine clinical trial samples and data will empower 
data analysis and the significance of any biomarkers 
identified.
A biomarker with clinical relevance requires rigor-
ous validation which can be separated into several 
sequential steps: assessment of basic assay perfor-
mance (analytical validation); characterization of the 
assay performance with regard to its intended use 
(clinical validation); validation in clinical trials that 
ensures that the assay performs robustly according 
to predefined specifications (fit-for-purpose) and the 
establishment of definitive acceptance criteria for 
clinical use (validation of clinical utility). The fit-for 
purpose approach (an umbrella term used to describe 
distinct stages of the validation process) for biomarker 
development and validation addresses the proper 
assay tailored to meet the intended purpose of the 
biomarker. The Society for Immunotherapy of Can-
cer (SITC) Immune Biomarkers Task Force convened 
to address this need in this two-volume series; pre-
analytical and analytical (Volume I) as well as clinical 
and regulatory (Volume II) aspects of the validation 
process as applied to predictive biomarkers for cancer 
immunotherapy [1, 2].
Clinical study design in which biomarker analysis is 
one of the primary objectives/endpoints needs to be pro-
moted. A good example of such a study was CA184-004 
(NCT00261365), a phase II trial to determine predictive 
markers of response to ipilimumab (MDX-010). In this 
study, the primary endpoint was to identify candidate 
markers predictive of response and/or serious toxicity 
to ipilimumab. Tissue and blood samples were collected 
at different time points from enrolled patients and the 
subsequent biomarker analyses generated interesting 
data. The findings of this study could have been consid-
ered as the first evidence for biomarker association with 
outcome, and could potentially have been confirmed and 
prospectively validated in subsequent studies. However, 
study results can often not sufficiently meet expectations 
or may be contradictory, which may be in part due to the 
constraints of underpowered cohort size, variables in 
the time and type of sample collection, and differences 
in procedures, data generation and tools used at differ-
ent sites. The opportunity to design parallel biomarker 
studies that are integrated as key components of impor-
tant randomized clinical trials could offer a solution. 
Sample collection (fresh and/or archival tissue, PBMC, 
serum, plasma, stool, etc.) at specific stages of treatment 
is important to evaluate possible biomarkers and to 
study mechanisms of response, resistance, toxicity and 
relapse. Such studies would be helpful in the design and 
development of upcoming therapies. At present, several 
research institutes around the world, including many at 
which the authors of this article are based, are collect-
ing tumor, blood, serum and faecal samples to investi-
gate prognostic and predictive biomarkers and to better 
understand the complex immunobiology of patients and 
their cancers.
Biomarker discovery is a fundamental objective in 
the design of many clinical trials. Therefore, the incor-
poration of correlative biomarker studies using state-
of-the-art technologies within clinical trials in order to 
maximize data generation is required. The challenge at 
this stage is that most completed or ongoing clinical trials 
have not sufficiently incorporated biomarker assessment 
into their design. There is a need for an international 
joint effort to maximize data, information and knowledge 
generation from existing and completed clinical trials 
and to design clinical trials that will better address these 
important issues.
The proposal of this white paper is to encourage the 
creation of a network to facilitate the sharing and coor-
dinating of samples from clinical trials in order to allow 
more in-depth analyses of correlative biomarkers than is 
currently possible. The feasibility, logistics, and various 
stakeholder interests in such a network are also consid-
ered. A high standard of sample collection and storage as 
well as the exchange of samples and knowledge through 
collaboration is proposed, and we envisage how this 
could move forward with banked samples from com-
pleted studies as well as with the prospective planning of 
ongoing and future clinical trials.
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Concept 2. The proposal of an international cancer 
immunotherapy biomarker consortium
There are a number of compelling arguments for the 
establishment of an international cancer immuno-
therapy biomarker consortium, which are summarized 
below.
1. To maximize the potential of novel biomarker dis-
covery using samples from multi-institutional clini-
cal practice and clinical studies and will offer a new 
breadth of experience and expertise to biomarker 
studies.
2. To allow streamlined sample access by developing 
online registration, biobanking, and the inventory 
and tracking of archived samples in order to best 
utilize samples existing after designated trials com-
pleted.
3. To set up and share standard operating procedures 
(SOPs) to harmonize future sample collection pro-
cessing and banking.
4. To improve access to samples by initiating a new 
patient sample registry or by joining forces with 
existing international clinical trial patient registries 
with available clinical data and biological sample 
collection, including storage conditions and inven-
tory information.
5. To provide support/guidelines in correlative study 
design.
6. To engage and leverage with cancer societies, 
pharma and biotech companies, and government 
institutes in order to improve the development of 
biomarkers.
7. To accelerate biomarker development by bringing 
together groups from around the world that can col-
laborate from proof-of-concept to validation. More-
over, the experience of the immunoscore worldwide 
project, coordinated by SITC, is an important exam-
ple of an ‘honest broker’ approach for coordinating 
a specific study and data sharing [3].
8. To reinforce the concept of a stable-standing con-
sortium which would be able to take a short, inter-
mediate and long-term view towards biomarker 
development for more effective care of patients with 
cancer.
In order to emphasize the point 4# proposal above and 
to have data on as large a group of patients as possible, it 
would be very beneficial to have a stable-standing consor-
tium among the major contributing institutions, societies 
and research centers. Recently, a consortium organized 
by The University of Tubingen was able to collect sam-
ples from several different institutions and obtain results 
from a large number of patients treated with Ipilimumab 
or an anti-PD-1 (Nivolumab or Pembrolizumab) [4]. The 
worldwide Immunoscore project is another good exam-
ple of a effective consortium that was successful at vali-
dating a previously described biomarker [3].
Concept 3. The challenges in biomarker discovery
A series of challenges are confronted when a project of 
this magnitude is proposed:
1. Limited or fragmented resources.
2. Insufficient numbers of patients per cohort.
3. Inclusion of patients with diverse treatment history 
(previous antitumoral treatment), histological and 
radiographic conditions.
4. Limited and/or suboptimal correlative study design 
due to funding and/or regulatory constraints.
5. Heterogeneity in the types of biological samples with 
different time points of collection, storage condi-
tions, platforms used for data generation, lab-driven 
SOPs and data analysis algorithms and tools.
6. Heterogeneity in the clinical data collected and the 
length of follow-up,
7. Lack of international joint initiatives.
8. Potential intellectual property.
Previous programs that utilized treatment stratifica-
tion biomarkers had higher success rates at each phase of 
development versus the overall dataset [5]. Moreover, the 
importance of determining biomarkers for both patient 
selection for treatment and selection of treatment for the 
patient is of utmost importance. As an example, assess-
ment of tumor PD-L1 status is not critical for selecting 
patients with metastatic melanoma for treatment with 
anti-PD-1 inhibitors (Pembrolizumab or Nivolumab). In 
fact, patients with PD-L1 negative tumors may receive 
long-term benefit from anti-PD-1/PD-L1 treatment. 
However, PD-L1 status might be important for selecting 
patients for combination treatment (e.g. anti-CTLA-4 
and anti-PD-1). Currently available data show that over-
all survival (OS) in PD-L1 positive patients treated with 
combined anti-CTLA-4 and anti-PD-1 is not superior 
to nivolumab monotherapy. This finding raises the ques-
tion of why should these patients be treated with a more 
toxic regimen if the same benefit is achieved with less 
toxic monotherapy? However, PD-L1 expression is not 
the best example of a biomarker for patient selection in 
the context of checkpoint inhibitors. Although patients 
with strongly positive (>  50% on tumor cells) PD-L1 
tumors clearly had an advantage for anti-PD-1 therapy 
versus chemotherapy in the Keynote 024 study, it is less 
clear why the same patient population did not show the 
same advantage from nivolumab therapy in the Check-
Mate 026 pivotal study [6]. Anti-PD-1/PD-L1 treatments 
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showed similar efficacy across different clinical trials and 
the problem may be in the IHC assay and the ‘immuno-
logical’ characterization/criteria used to evaluate PD-L1 
positivity. However, the FDA recently (11th May 2017) 
approved the combination of chemotherapy with pem-
brolizumab for first-line treatment of NSCLC regardless 
of PD-L1 expression, confirming the need for predictive 
biomarkers [7].
Over 10  years ago, the FDA issued important guid-
ance that all drugs should be accompanied by a com-
panion diagnostic (CDx). Industry has applied a 
thorough understanding of biology and the immune 
system to develop robust and meaningful biomarkers. 
While industry may believe that leveraging biomark-
ers and companion diagnostics are critical to precision 
medicine, developing them is challenging and expen-
sive and therefore has been less of a priority. On the 
other hand, the introduction of Pembrolizumab in 
clinical trials should be an example to others. Indus-
try efforts might be helped by strategic partnerships 
with academic institutions in order to identify rel-
evant clinical biomarkers. For example, the processes 
of detecting reproducible, predictive biomarkers and 
developing robust companion diagnostics substan-
tially benefit from the correlation to genomics and 
complex tissue analysis data. This includes the analy-
sis of spatial relationships between immune cells host-
ing the tumour environment and the development of 
highly sensitive, precise, quantifiable and reproducible 
assays. These issues are challenging, time-consuming 
and need large investment. Pursuing a thorough, evi-
dence-based and scientifically-driven drug discovery 
and development program is the desired long-term 
goal. However, funds to support these programs could 
be used for more short-term plans such as recruiting 
additional patient groups into a clinical trial in order 
to meet regulatory objectives.
At present, the best example of a truly successful and 
important immune-oncology predictive biomarker 
is mismatch repair deficiency: Cancer patients with 
microsatellite instability high (MSI-H) tumors inde-
pendent of the tissue of origin benefit from immu-
notherapy with PD-1 inhibitors [8]. In particular, in 
colorectal cancer, MSI-H patients experience up to 50% 
or higher responses, while few if any responses are seen 
in MSI-low (L) colorectal cancer patients. Clinical dem-
onstration of this concept has led to a recent approval 
by the FDA. We believe that these two examples of sin-
gle predictive biomarkers (i.e. PD-L1 and MSI) will be 
the exception and not the rule and that we will have to 
search for the integration of several different biomark-
ers. This will amplify the challenge and will require a 
highly coordinated effort across multiple institutions.
Patient inclusion and statistical considerations according 
to the study design
The development and implementation of appropriate 
biomarker assays to study T cells and other cells in the 
microenvironment is an essential companion objective 
for clinical trials that seek to evaluate immunothera-
peutic agents, particularly when used in combination. 
In principle, the efficacy of a compound (in this case 
immune-targeted agents) is at least partially dependent 
on the presence of the target in the tumor. In an ideal 
scenario, when complete information on predictive fac-
tors and proper selection of patients can be obtained in 
the early phases of drug development (phase I–II stud-
ies), the conduct of subsequent phase III studies could 
be optimized. Unfortunately, this ideal scenario rarely 
occurs. The clinical immune-oncology research commu-
nity is dealing with several key questions, including; (a) 
what metrics are best for biomarker evaluation in phase 
III studies, (b) what primary and secondary endpoints 
should ne assessed, and (c) what are the statistical prop-
erties of various metrics. When planning a phase III trial 
comparing an experimental treatment with the standard, 
we often have evidence supporting a predictive role of 
a biomarker, whereas patients with the absence of such 
expression should not respond. In such a scenario, dif-
ferent strategies are theoretically possible (see Fig.  1): 
(i) a ‘randomize all’ strategy, i.e. randomization between 
standard and experimental treatment without selection, 
possibly with stratification based on biomarker status 
(in this case, ‘stratified trial design’ or ‘treatment-marker 
interaction design’); (ii) ‘targeted’ design, i.e. randomiza-
tion between standard and experimental treatment only 
in patients selected according to the status of the marker 
(also called ‘enrichment design’); and (iii) ‘customized’ 
strategy (also called ‘marker-based strategy’), i.e. ran-
domization between a standard arm in which the treat-
ment is the same for all patients, and a personalized arm 
in which treatment is chosen on the basis of the marker 
status of each patient.
How can we develop a predictive biomarker in a more 
efficient way? The experience of the worldwide con-
sortium on Immunoscore could be leading the way in 
finding different trial methods for evaluating immune-
oncology biomarkers. We could also consider an opposite 
approach to the classical flow suggested in Fig. 1 in which 
biomarkers are validated first. The challenge in this case 
is in the ability of statistics to find the correct solutions 
and avoid decades-long clinical trials. Since biomark-
ers have been validated preclinically they could be used 
in different cohort studies for clinical predictive analy-
sis. This could immediately eliminate the lack of effec-
tive information in those markers that do not reach the 
desired endpoint.
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Fig. 1 Procedures for discovery and validation of biomarkers. Alternative designs of randomized phase III trials in the presence of a potentially pre-
dictive marker of efficacy of treatment. BM + , positive biomarker; BM − , biomarker negative. Bottom left, “randomize-all” design with determina-
tion and prospective stratification of BM + and BM − patients. Center, “targeted” design. Right, “customized” design
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Methods
To address these challenges, a systematic approach 
involving a multi-institutional effort could help identify 
and develop robust, standardized biomarkers and related 
clinical data that support the selection and testing of 
promising therapeutic approaches and combinations. The 
diversity of reagents and platforms that are being used to 
assess the immune systems of humans and data report-
ing procedures are not consistent. This hampers data 
reproducibility among laboratories, which may prevent 
meaningful interpretations across studies and could lead 
to selection of different intent-to-treat (ITT) populations. 
Most of the assays being used involve high-throughput 
multi-parametric ‘signatures’ that require considerable 
statistical and bioinformatic efforts for proper algorithm 
development and robust data interpretation. The requi-
site capabilities are not available to all investigators assay-
ing immune biomarkers and are not consistently being 
accomplished in academic or clinical laboratories due 
to resource constraints. This issue must be addressed to 
ensure that biomarker measurements using high-quality, 
validated assays can be compared between clinical trials. 
The use of different assays, if there are standards or ref-
erence materials available, could allow for evaluation and 
comparison of performance across the assays and across 
different sites. There is no current system that can easily 
integrate analyses across different clinical trials.
Different approaches to overcome these limitations and 
to address different technical and logistical challenges 
have evolved in the process of biomarker standardization.
a. A central laboratory approach is able to provide 
integrated testing, sample management, and data-
management services; therefore, it may be able to 
supply efficient and reliable biomarker testing and 
data delivery as part of comprehensive biomarker 
characterization. A small, integrated network of labo-
ratories with specific expertise in an array of molecu-
lar and cellular approaches, testing blood and tumor 
samples, would be able to support coordinated and 
standardized biomarker investigation, sample sharing 
and data sharing.
b. An alternative approach that facilitates the compa-
rability and integration of data across multiple labo-
ratories is assay harmonization (proficiency panel-
driven SOPs, approaches and troubleshooting). 
Harmonization of biomarker assays enforces iden-
tical reagents and/or protocols across laboratories 
and the establishment of assay-specific protocols in 
individual laboratories. The harmonization process 
involves the participation of multiple laboratories in 
a consortium-based iterative testing process to iden-
tify the variables crucial for assay performance, with 
data sharing and sometimes centralized analysis. The 
‘Immunoscore’ validation initiative is an example of 
this approach.
c. An example that addresses comparability of 
approach across multiple IHC-based PD-L1 tests was 
addressed by the Blueprint Project developed by four 
pharmaceutical companies (Bristol-Myers Squibb, 
Merck & Co. Inc., AstraZeneca PLC, and Genentech, 
Inc.) [9].
The network
Samples associated with clinical outcomes from clinical 
practice or clinical studies are an enormous resource for 
the identification of biomarkers that is often underuti-
lized. We propose developing an International Immuno-
therapy Biomarkers Consortium to overcome barriers to 
the use of these samples and associated clinical informa-
tion and to optimize the information that can be learned 
from them. This can help the development of biomark-
ers from proof-of-concept to validation. Moreover, 
the experience of the Immunoscore worldwide project 
coordinated by SITC is an important example of how to 
work in this field. The network should be a permanent 
consortium with a virtual biobank that can be accessed 
as soon as an investigator from the Consortium has a sci-
entifically valid idea. Suggestions for such a consortium 
include:
1. A survey to establish the need and willingness of dif-
ferent institutions to participate with time, reagents, 
and sample sets. This would involve development of 
a subcommittee to explore issues and strategies for 
sharing licensing and royalty income for IPs devel-
oped from the consortium with centers who partici-
pate in providing tissue samples and scientific exper-
tise.
2. A database and registry of ongoing international clin-
ical trials; clinical information including outcome; 
survey of sample type and availability; clinical and 
experimental data have already been completed [4]. 
This exercise will help identify gaps, unify standards 
and understand the willingness of participants.
3. A committee to propose overall direction and iden-
tify projects to pursue, based on data-based informa-
tion and sample availability. Other responsibilities of 
this committee would include:
a. Announcing survey results and providing data-
base access to all participants.
b. Requesting proposals from participants and the 
broader community.
c. Seeking sponsorship from venture capital, 
pharma, society, and private funding (with the 
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possibility to have exclusive rights to develop 
companion diagnostics).
d. Review proposals and grant-selected projects 
with sample access for phase I discovery up to 
phase III validation studies. The consortium 
will develop policies and procedures to ensure 
that samples will be used in the most effective, 
ethical way and to maximize data generation 
and knowledge generation using state-of-the-art 
methodology germline and somatic genetic anal-
ysis (SNP, NGS, CNV, TCR).
i. Epigenetics (transcription, methylation, miRNA, 
splicing variation, fusion transcripts, transcription 
regulation).
ii. Proteomics (serum/plasma protein profiling, cytokine 
assays, antibody screen, exosome analysis,
iii. Metabolomic profiling.
iv. Microbiome/virome analysis.
v. Flow cytometry, Single cell network analysis, sorted 
cells, functional and phenotypic profiling.
vi. Evaluation of the tumor and relationship of immune 
cells with image analysis and machine learning (Mul-
tiplex IHC, Immunoscore, CyTOF).
vii. Pharmacogenomics.
viii. ImmunoPET.
e. Monitor project progression and outcome.
f. Present updates to the consortium at interna-
tional meetings.
g. Publish results of discovery as a consortium 
in an open access journal and make databases 
available in format similar to TCGA.
h. Coordinate biomarker validation.
Objectives
Objectives of this consortium are outlined below.
  • The creation of a database of available samples, with 
linked key information would be a top priority. This 
effort could start with the trial titles/therapeutics 
tested and basic trial design, number of patients, 
timepoints and the nature of biospecimens obtained, 
for a first review.
  • Every participant would keep the samples on site but 
provide the information on this centralized database. An 
app that facilitates the collection of the data preserving 
the deidentified nature of the information is essential. 
This could also be designed to allow a relevant search 
engine to find samples based on specific characteristics.
  • A committee would evaluate proposals after samples 
have been identified that may be suitable for a spe-
cific project.
  • A network of bioinformaticians would be established 
with the purpose of developing new algorithms capa-
ble to interpret and integrate data coming from the 
analysis of different parameters/biomarkers (Fig. 2).
  • A task force should be created with the intent to 
facilitate the discovery and development of predictive 
biomarkers.
Discussion
The main goal of this white paper is to develop the frame-
work for a network of institutes with widespread sharing 
of available samples and clinical data. This will facilitate 
the exchange of knowledge and collaboration in suggest-
ing upcoming clinical trials.
There are ongoing projects that could be partners such 
as the Foundation for the NIH Biomarker Consortium, 
in which projects are discussed among biomarker spe-
cialists, but then funded through collaborative industry 
funding in a ‘pre-competitive space’ where companion 
diagnostics are not yet ready to be developed by indi-
vidual companies. In addition, the four existing working 
groups of the SITC Immunotherapy Biomarkers Task 
Force (http://sitc.sitcancer.org/about-sitc/initiatives) cur-
rently consist of a broad array of expertise in standardi-
zation and validation of biomarkers, new technologies, 
systematic high throughput approaches and baseline and 
tumor-focused biomarkers. In concert with these central-
ized steering committees, the involved academic centers 
that have clinical trials and individual biomarker exper-
tise, would discuss what they have banked and what pro-
jects could be performed together.
Although it is relatively straightforward to create an 
Internal Cancer Immunotherapy Consortium, the major 
challenge is to execute the plan or methods of the net-
work as described here. This requires stepwise planning 
and strategies based upon ‘what you have’ to ‘how you 
do’ to ‘what you could offer’ to ‘all we could achieve’. Both 
the central laboratory approach and alternative approach 
could start with retrospective biomarker analyses based 
upon samples which have been collected from immuno-
therapy trials from sites participating in the consortium, 
in order to highlight the quality of biomarker work from 
this consortium. The consortium could then work with 
pharmaceutical companies to launch potential prospec-
tive clinical trials to validate biomarkers. In addition, 
following the achievements of PD-L1 companion diag-
nostics for cancer immunotherapy, the consortium could 
initiate and facilitate efforts on transferring validated 
biomarkers such as RNA expression profile, tumor muta-
tional burden to companion diagnostics. A clear, feasi-
ble and effective strategy will ensure the success of this 
consortium.
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The concept of a network of collaborating biomarker 
discovery/validation efforts raises the critical question 
of potential mechanisms for financing this effort. Several 
initiatives are already emerging in this arena. In spring 
2017 in the USA, the NCI initiated an effort that is sup-
ported with funds from the Beau Biden Cancer Moon-
shot Initiative (through peer review and NCI-support) 
for four separate laboratory centers to function as Clini-
cal Immunotherapy Monitoring and Assessment Centers 
(CIMACs). However, the CIMAC laboratories network 
will serve NCI clinical trials in immunotherapy and 
would not have the capacity to integrate with other clini-
cal trial networks/consortia. Perhaps in the future with 
more funding and expanded infrastructure this would be 
possible. These laboratory networks will engage in sepa-
rate yet integrated laboratory activities using established 
and innovative platforms to evaluate both biomarkers 
and other surrogate endpoints for ongoing and future 
NCI sponsored cancer immunotherapy studies. This 
network could serve as an important model for correla-
tive study infrastructure in other clinical trial networks 
and expanded interactions and coordination with other 
immune-oncology clinical laboratories for assessment 
and monitoring of biomarkers, at a global level.
The suggested international consortium for estab-
lishing and validating predictive biomarkers could 
Fig. 2 Reconstruction from Fig. 1
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participate in correlative biomarker science in clinical 
trials and also post-trial analyses in a systematic manner. 
This consortium could be very closely connected with 
clinical trials in immunotherapy including existing net-
works (e.g. the NCI supported Cancer Immunotherapy 
Trial Network, CITN) and all other ongoing trials in the 
US and Europe. Most trials will likely be small cohort 
studies. The consortium could combine several types of 
trials and analyze them across studies in an interdiscipli-
nary approach. It is important to keep in mind possible 
bottlenecks. For instance, the US National Clinical Tri-
als Network (NCTN, formerly the cooperative groups) 
has been attempting to develop a shared database across 
multiple specimen banks for some time and has found it 
to be a very complex task. Different institutes track dif-
ferent sample parameters and sharing any patient identi-
fiers will be a concern with regard to privacy regulations. 
This is an issue that might be solved by applying similar 
parameters to categorize samples collected at each insti-
tution. Another example is the database for the pediat-
ric brain cancer consortium, run at CHOP (Children’s 
Hospital of Philadelphia) using RedCap software with 
restricted consortium-only access [10]. While this is fea-
sible, it requires expertise and personnel with dedicated 
effort.
In order to maintain solid communication and up-
to-date information flow, the consortium could have 
monthly discussions and generate white papers summa-
rizing promising data and outlining validation that could 
become high priority research initiatives to be taken on 
by the consortium or by other larger clinical trial groups 
with the capacity for such larger studies.
There are many important details that will require 
resolution in order to initiate a functional consortium 
able to pursue even a fraction of the objectives identified 
as important in this report. Moving forward will ben-
efit from face-to-face discussions among a committed 
group of stakeholders, consisting of immune-oncology 
researchers with expertise in preclinical testing, clini-
cal trials, and state-of-the-art laboratory evaluations 
of preclinical and clinical immunotherapy regimens. 
Convening a full-day workshop of such stakeholders, 
potentially at a SITC meeting, or a separate meeting of 
worldwide leaders in immune-oncology, may provide 
the time, focus, discussions, and interactions needed to 
help convert some of the helpful goals and concepts pre-
sented here into a prioritized action plan that might help 
promote this vision and enable additional next steps to 
proceed.
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